GSK3B and Alzheimer disease: Multitarget directedligands are being developed to simultaneously target key pathologicalpathways, such as the combination of GSK-3β/DYRK1A or AChE/GSK-3β. These efforts reflect a shift from single-target to systems-levelinterventions. Alshabrmi et al. integratedML and network pharmacology approachesto identify potential therapeutic compounds targeting two key proteins,MTOR and BCL2, for AD.